| Year |
Citation |
Score |
| 2020 |
Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, Izatt T, Trent JM, Byron S, Pal S. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. Journal For Immunotherapy of Cancer. 8. PMID 32661119 DOI: 10.1136/Jitc-2020-000953 |
0.36 |
|
| 2020 |
Salgia N, Dizman N, Lyou Y, Bergerot PG, Hsu J, Byron SA, Trent JM, Pal SK. Genomic and transcriptomic correlates of clinical benefit from immunotherapy and targeted therapy among patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 38: 5076-5076. DOI: 10.1200/Jco.2020.38.15_Suppl.5076 |
0.306 |
|
| 2019 |
Berens ME, Sood A, Barnholtz-Sloan JS, Graf JF, Cho S, Kim S, Kiefer J, Byron SA, Halperin RF, Nasser S, Adkins J, Cuyugan L, Devine K, Ostrom Q, Couce M, et al. Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. Plos One. 14: e0219724. PMID 31881020 DOI: 10.1371/Journal.Pone.0219724 |
0.37 |
|
| 2019 |
Roos A, Byron SA. Genomics-Enabled Precision Medicine for Cancer. Cancer Treatment and Research. 178: 137-169. PMID 31209844 DOI: 10.1007/978-3-030-16391-4_5 |
0.37 |
|
| 2019 |
Halperin RF, Liang WS, Kulkarni S, Tassone EE, Adkins J, Enriquez D, Tran NL, Hank NC, Newell J, Kodira C, Korn R, Berens ME, Kim S, Byron SA. Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples. Frontiers in Oncology. 9: 119. PMID 30949446 DOI: 10.3389/Fonc.2019.00119 |
0.325 |
|
| 2019 |
Mueller S, Jain P, Liang WS, Kilburn L, Kline C, Gupta N, Panditharatna E, Magge SN, Zhang B, Zhu Y, Crawford JR, Banerjee A, Nazemi K, Packer RJ, Petritsch CK, ... ... Byron SA, et al. A pilot precision medicine trial for children with diffuse intrinsic pontine glioma - PNOC003: a report from the Pacific Pediatric Neuro-Oncology Consortium. International Journal of Cancer. PMID 30861105 DOI: 10.1002/Ijc.32258 |
0.359 |
|
| 2018 |
Packer LM, Stehbens SJ, Bonazzi VF, Gunter JH, Ju RJ, Ward M, Gartside MG, Byron SA, Pollock PM. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer. Molecular Oncology. PMID 30537101 DOI: 10.1002/1878-0261.12422 |
0.393 |
|
| 2018 |
Babiker HM, Byron SA, Hendricks WPD, Elmquist WF, Gampa G, Vondrak J, Aldrich J, Cuyugan L, Adkins J, De Luca V, Tibes R, Borad MJ, Marceau K, Myers TJ, Paradiso LJ, et al. E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. Investigational New Drugs. PMID 30264293 DOI: 10.1007/S10637-018-0668-8 |
0.335 |
|
| 2018 |
Berens ME, Barnholtz-Sloan JS, Rusu M, Graf J, Sood A, Cho S, Zavodszky M, Byron S, Halperin R, Fritz Y, Kim S, Ginty F. Abstract 3039: Role of IDH mutation status on molecular and spatial heterogeneity in glial tumors across progression and recurrence Cancer Research. 78: 3039-3039. DOI: 10.1158/1538-7445.Am2018-3039 |
0.382 |
|
| 2018 |
Peng S, Halperin R, Dhruv H, Byron S, Legendre C, Phillips J, Prados M, Berens M, Tran N. Abstract 289: Probing the non-enhancing component of glioblastoma: Targeting what is left behind Cancer Research. 78: 289-289. DOI: 10.1158/1538-7445.Am2018-289 |
0.368 |
|
| 2018 |
Packer L, Byron S, Stehbens S, Bonazzi V, Loch D, Wortmann A, Gartside M, Waterhouse N, Gunter J, Pollock PM. Abstract LB-B31: FGFR inhibition in endometrial cancer induces caspase-independent cell death that can be augmented with ABT-737 Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Lb-B31 |
0.419 |
|
| 2017 |
Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski N, Taylor J, Clarke JL, Chang SM, et al. Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29074604 DOI: 10.1158/1078-0432.Ccr-17-0963 |
0.32 |
|
| 2017 |
Halperin RF, Carpten JD, Manojlovic Z, Aldrich J, Keats J, Byron S, Liang WS, Russell M, Enriquez D, Claasen A, Cherni I, Awuah B, Oppong J, Wicha MS, Newman LA, et al. A method to reduce ancestry related germline false positives in tumor only somatic variant calling. Bmc Medical Genomics. 10: 61. PMID 29052513 DOI: 10.1186/S12920-017-0296-8 |
0.345 |
|
| 2017 |
Weiss GJ, Byron SA, Aldrich J, Sangal A, Barilla H, Kiefer JA, Carpten JD, Craig DW, Whitsett TG. A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapy. Plos One. 12: e0179170. PMID 28586388 DOI: 10.1371/Journal.Pone.0179170 |
0.37 |
|
| 2017 |
Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron SA, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle JD, Gambara G, Gallagher RI, Dunetz B, et al. Enrichment of PIK3-AKT-MTOR pathway activation in hepatic metastases from breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28446508 DOI: 10.1158/1078-0432.Ccr-16-2656 |
0.43 |
|
| 2017 |
Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, et al. FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. PMID 28314589 DOI: 10.1016/J.Ygyno.2017.02.031 |
0.364 |
|
| 2017 |
Pierobon M, Wong S, Reeded A, Anthony S, Robert N, Northfelt D, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Carpten J, et al. Abstract P1-07-09: A multi-OMIC analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: Clinical implication for precision medicine in metastatic breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-07-09 |
0.413 |
|
| 2017 |
Weiss G, Sangal A, Barilla H, Byron S, Kiefer J, Aldrich J, Whitsett T, Carpten J, Craig D. MA11.10 Prospective Study of Genome-Wide Strexome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.468 |
0.35 |
|
| 2016 |
Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/Journal.Pone.0150564 |
0.679 |
|
| 2016 |
Prados M, Kuhn JG, Colman H, Cloughesy TF, Chang SM, Butowski NA, De Groot JF, Wen PY, Ligon KL, Mellinghoff IK, Chi AS, Phillips JJ, Molinaro AM, Halperin R, Tran N, ... ... Byron SA, et al. Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium. Journal of Clinical Oncology. 34: 2031-2031. DOI: 10.1200/Jco.2016.34.15_Suppl.2031 |
0.331 |
|
| 2016 |
Pierobon M, Wong S, Reeder A, Anthony S, Robert N, Northfelt D, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Petricoin E, et al. Abstract P2-05-21: The AKT-mTOR pathway as a potential organ-specific drug target signature of hepatic metastases from breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-05-21 |
0.405 |
|
| 2016 |
Kuhn J, Chen R, Clarke J, Chang S, Cloughesy T, Colman H, Wen P, Mellinghoff I, Ligon K, Groot Jd, Batchelor T, Omuro A, Taylor J, Butowski N, Halperin R, ... ... Byron S, et al. MPTH-01. ARE MUTATIONS IN MISMATCH REPAIR (MMR) GENES OUR NEXT BIOMARKER OF ALKYLATING AGENT INDUCED HYPERMUTATOR PHENOTYPE? PRELIMINARY RESULTS FROM THE IVY PRECISION TRIAL Neuro-Oncology. 18: vi105-vi105. DOI: 10.1093/Neuonc/Now212.440 |
0.312 |
|
| 2016 |
Mueller S, Liang W, Gupta N, Kuhn J, Kilburn L, Crawford J, Banerjee A, Nazemi K, Packer R, Nazarian J, Petritsch C, Truffaux N, Roos A, Nicolaides T, Waanders A, ... ... Byron S, et al. Hg-115Precision Medicine Approach For Children With Diffuse Intrinsic Pontine Glioma Neuro-Oncology. 18. DOI: 10.1093/Neuonc/Now073.111 |
0.341 |
|
| 2015 |
Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-Oncology. 17: 1051-63. PMID 25934816 DOI: 10.1093/Neuonc/Nov031 |
0.375 |
|
| 2014 |
Park JB, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, Smith CA, Byron S, Zadeh G, Croul S, Berens M, Rutka JT. Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. Oncotarget. 5: 9382-95. PMID 25237832 DOI: 10.18632/Oncotarget.2412 |
0.356 |
|
| 2014 |
Packer LM, Byron S, Loch D, Dehkhoda F, Wortmann A, Geng X, Nones K, Grimmond S, Pearson J, Waddell N, Pollock P. Abstract 1715: Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancer Cancer Research. 74: 1715-1715. DOI: 10.1158/1538-7445.Am2014-1715 |
0.39 |
|
| 2014 |
Mueller S, Liang W, Byron S, Nazemi K, Leary S, Kilburn L, Prados M, Gupta N, Craig D, Carpten J, Berens M. Pl-03Feasibility Of Genomics-Enabled Therapy For Pediatric High-Grade Gliomas And Diffuse Pontine Gliomas. Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou267.3 |
0.387 |
|
| 2014 |
Berens M, Armstrong B, Peng S, Ross J, Salhia B, Byron S, Virk S, Dhruv H, Tran N, Sloan A, Ostrom Q, Barnholtz-Sloan J. GE-03 * GENOMIC CHARACTERIZATION OF SURVIVAL OUTLIERS IN GLIOBLASTOMA MULTIFORME Neuro-Oncology. 16: v96-v96. DOI: 10.1093/Neuonc/Nou256.3 |
0.333 |
|
| 2014 |
Ma D, Sarkaria J, Peng S, Byron S, Craig D, Carpten J, Berens M, O'Neill B, Schroeder M, Tran N. Ge-19Genomics Guided Therapeutic Approach For The Treatment Of Glioblastoma Multiforme (Gbm) Using Next Generation Sequencing (Ngs) Technologies Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou256.18 |
0.379 |
|
| 2014 |
Johnson KN, Gooden G, Gonzalez P, Sepulveda M, Gorgol L, Petricoin EF, Pierobon M, Byron S, Glen J, Ahluwalia M, Bernstein M, Toms SA, Salhia B. BM-15 * TARGETING MEK IS A NOVEL AND EFFECTIVE TREATMENT STRATEGY OF LUNG CNS METASTASIS Neuro-Oncology. 16: v35-v35. DOI: 10.1093/Neuonc/Nou240.15 |
0.4 |
|
| 2013 |
Byron SA, Chen H, Wortmann A, Loch D, Gartside MG, Dehkhoda F, Blais SP, Neubert TA, Mohammadi M, Pollock PM. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia (New York, N.Y.). 15: 975-88. PMID 23908597 DOI: 10.1593/Neo.121106 |
0.355 |
|
| 2013 |
Doudican NA, Byron SA, Pollock PM, Orlow SJ. XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts. Anti-Cancer Drugs. 24: 181-8. PMID 23059386 DOI: 10.1097/Cad.0B013E32835A43F1 |
0.319 |
|
| 2012 |
Byron SA, Loch DC, Pollock PM. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 22: 1517-26. PMID 23060048 DOI: 10.1097/Igc.0B013E31826F6806 |
0.478 |
|
| 2012 |
Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim S. Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer. Plos One. 7: e46823. PMID 23056468 DOI: 10.1371/Journal.Pone.0046823 |
0.458 |
|
| 2012 |
Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, Nomoto K, Pollock PM. Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Molecular Cancer. 11: 75. PMID 23039341 DOI: 10.1186/1476-4598-11-75 |
0.378 |
|
| 2012 |
Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, Pollock PM. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. Plos One. 7: e30801. PMID 22383975 DOI: 10.1371/Journal.Pone.0030801 |
0.357 |
|
| 2012 |
Doudican NA, Byron S, Pollock P, Orlow SJ. Abstract 4893: XIAP downregulation accompanies inhibition of melanoma xenograft growth by mebendazole Cancer Research. 72: 4893-4893. DOI: 10.1158/1538-7445.Am2012-4893 |
0.394 |
|
| 2012 |
Loch D, Byron S, Wortman A, Chen H, Mohammadi M, Pollock P. Abstract A61: Profile of Ponatinib, BGJ398, AZ4547 and DCC-2036 against FGFR2 Mutations identified in a Dovitinib Resistance BaF3 Screen Clinical Cancer Research. 18: A61-A61. DOI: 10.1158/1078-0432.Mechres-A61 |
0.409 |
|
| 2011 |
Byron SA, Chen H, Mohammadi M, Pollock PM. Abstract 4733: Activating FGFR2 kinase domain mutations provide resistance to dovitinib (TKI258) Cancer Research. 71: 4733-4733. DOI: 10.1158/1538-7445.Am2011-4733 |
0.417 |
|
| 2010 |
Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecologic Oncology. 117: 125-9. PMID 20106510 DOI: 10.1016/J.Ygyno.2009.12.002 |
0.414 |
|
| 2010 |
Doudican NA, Pennell R, Byron S, Pollock P, Liebes L, Osman I, Orlow S. Mebendazole in the treatment of melanoma: The role of Bcl-2 in predicting response and enhancing efficacy. Journal of Clinical Oncology. 28: e19021-e19021. DOI: 10.1200/Jco.2010.28.15_Suppl.E19021 |
0.348 |
|
| 2009 |
Kalinina J, Byron SA, Makarenkova HP, Olsen SK, Eliseenkova AV, Larochelle WJ, Dhanabal M, Blais S, Ornitz DM, Day LA, Neubert TA, Pollock PM, Mohammadi M. Homodimerization controls the fibroblast growth factor 9 subfamily's receptor binding and heparan sulfate-dependent diffusion in the extracellular matrix. Molecular and Cellular Biology. 29: 4663-78. PMID 19564416 DOI: 10.1128/Mcb.01780-08 |
0.305 |
|
| 2009 |
Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncology (London, England). 5: 27-32. PMID 19243295 DOI: 10.2217/14796694.5.1.27 |
0.439 |
|
| 2009 |
Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Molecular Cancer Research : McR. 7: 41-54. PMID 19147536 DOI: 10.1158/1541-7786.Mcr-08-0021 |
0.392 |
|
| 2009 |
Byron SA, Gartside MG, Pollock PM. Abstract C86: FGFR inhibition potentiates the effect of conventional chemotherapeutic agents in endometrial cancer cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C86 |
0.475 |
|
| 2009 |
Byron S, Wellens C, Wu J, Wang J, Nomoto K, Pollock P. Abstract B93: Sensitivity to the MEK inhibitor, E6201, is associated with mutant BRAF status and is inversely correlated with pAKT expression levels in melanoma cell lines Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B93 |
0.389 |
|
| 2009 |
Becker M, Ibrahim Y, Byron S, Sarver A, Silverstein K, Lee A, Yee D. IGF-Induced Gene Profiles Are Dependent on IRS Expression and Convey Prognostic Value in Human Breast Cancer. Cancer Research. 69: 3031-3031. DOI: 10.1158/0008-5472.Sabcs-09-3031 |
0.676 |
|
| 2008 |
Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S, Tran E. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6146-53. PMID 18829493 DOI: 10.1158/1078-0432.Ccr-08-0509 |
0.355 |
|
| 2008 |
Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2. Molecular Cancer Research : McR. 6: 1491-8. PMID 18819936 DOI: 10.1158/1541-7786.Mcr-07-2173 |
0.616 |
|
| 2008 |
Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow PJ, Pollock PM. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Research. 68: 6902-7. PMID 18757403 DOI: 10.1158/0008-5472.Can-08-0770 |
0.448 |
|
| 2006 |
Byron SA, Horwitz KB, Richer JK, Lange CA, Zhang X, Yee D. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. British Journal of Cancer. 95: 1220-8. PMID 17043687 DOI: 10.1038/Sj.Bjc.6603354 |
0.621 |
|
| 2003 |
Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Seminars in Oncology. 30: 125-32. PMID 14613033 DOI: 10.1053/J.Seminoncol.2003.08.014 |
0.614 |
|
| Show low-probability matches. |